Birgit M. Rami-Merhar

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 83 publications

Differences in Achieving Stringent Glycemic Targets Among Youth with Type 1 Diabetes: A SWEET Registry Study.

Differences in Achieving Stringent Glycemic Targets Among Youth with Type 1 Diabetes: A SWEET Registry Study.

Journal: Diabetes technology & therapeutics

Published: July 02, 2026

Cambridge hybrid closed-loop use in very young children with type 1 diabetes: Parental expectancies during long-term home use.

Cambridge hybrid closed-loop use in very young children with type 1 diabetes: Parental expectancies during long-term home use.

Journal: Diabetic medicine : a journal of the British Diabetic Association

Published: April 01, 2026

Antihyperglycemic treatment of type 2 diabetes mellitus (Update 2026)

Antihyperglycemic treatment of type 2 diabetes mellitus (Update 2026)

Journal: Wiener klinische Wochenschrift

Published: January 02, 2026

Automated insulin delivery (AID) systems, physical activity and sports in type 1 diabetes mellitus: joint guidelines of the DDG and ÖDG

Automated insulin delivery (AID) systems, physical activity and sports in type 1 diabetes mellitus: joint guidelines of the DDG and ÖDG

Journal: Wiener klinische Wochenschrift

Published: October 14, 2025

Diabetes mellitus in childhood and adolescence (Update 2026)

Diabetes mellitus in childhood and adolescence (Update 2026)

Journal: Wiener klinische Wochenschrift

Published: October 07, 2025

Diabetes technology (Update 2026)

Diabetes technology (Update 2026)

Journal: Wiener klinische Wochenschrift

Published: September 10, 2025

Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.

Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.

Journal: Lancet (London, England)

Published: July 07, 2025

Head-to-Head Comparison of Two Automated Insulin Delivery Systems in Children with Type 1 Diabetes during a 2-Week Summer Camp: An Exploratory Prospective Study.

Head-to-Head Comparison of Two Automated Insulin Delivery Systems in Children with Type 1 Diabetes during a 2-Week Summer Camp: An Exploratory Prospective Study.

Journal: Hormone research in paediatrics

Published: June 28, 2025

The Use of Continuous Glucose Monitoring to Diagnose Stage 2 Type 1 Diabetes.

The Use of Continuous Glucose Monitoring to Diagnose Stage 2 Type 1 Diabetes.

Journal: Journal of diabetes science and technology

Published: May 30, 2025

Position paper: Open-source technology in the treatment of people living with diabetes mellitus-an Austrian perspective : Technology Committee of the Austrian Diabetes Association

Position paper: Open-source technology in the treatment of people living with diabetes mellitus-an Austrian perspective : Technology Committee of the Austrian Diabetes Association

Journal: Wiener klinische Wochenschrift

Published: July 01, 2024

Eighteen-Month Hybrid Closed-Loop Use in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Trial.

Eighteen-Month Hybrid Closed-Loop Use in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Trial.

Journal: Diabetes care

Published: June 24, 2024

Retrospective Comparison of Commercially Available Automated Insulin Delivery With Open-Source Automated Insulin Delivery Systems in Type 1 Diabetes.

Retrospective Comparison of Commercially Available Automated Insulin Delivery With Open-Source Automated Insulin Delivery Systems in Type 1 Diabetes.

Journal: Journal of diabetes science and technology

Published: February 17, 2024

Showing 1-12 of 83

Last Updated: 09/26/2026